ArticleAnnals of surgical oncology2026
Disaggregating Asian American and Pacific Islander Subpopulations in Esophageal Cancer: Stage, Histology, and Survival.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cancer-Specific and Other-Cause Mortality of Asian Pacific Islanders vs. Caucasians Across Eleven Primary Cancers.Journal of racial and ethnic health disparities · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsian American/Pacific Islander (AAPI) patients are typically aggregated together in esophageal cancer (EC) research, which may mask differences in risk factors, histology, and survival. This study analyzed EC characteristics and outcomes in disaggregated AAPI groups.
methodsUsing the National Cancer Database (2009-2020), we compared aggregated AAPI patients, regional subgroups (East Asian, etc.), and subpopulations (Chinese, Vietnamese, etc.) to non-Hispanic White (NHW) patients. Advanced stage (III-IV) at diagnosis and squamous cell carcinoma (SCC) histology were analyzed. After adjusting for sociodemographic factors, 3-year overall survival (OS) was assessed.
resultsA total of 3,254 AAPI patients with EC were compared with 156,801 NHW patients. Aggregated AAPI patients had higher odds of advanced stage disease (adjusted odds ratio [aOR] 1.12, 95% confidence interval [CI] 1.03-1.21, p = 0.006), higher odds of squamous cell carcinoma (aOR 4.63, 95% CI 4.28-5.01, p < 0.0001), and better 3-year OS (hazard ratio [HR] 0.87, 95% CI 0.82-0.91, p < 0.001). For regional subgroups, only Southeast Asian (aOR 1.46, 95% CI 1.22-1.75, p < 0.0001) and Pacific Islander (aOR 1.62, 95% CI 1.19-2.23, p = 0.003) patients had higher odds of advanced stage disease. For subpopulations, Vietnamese patients had the highest odds of SCC (aOR 8.90, 95% CI 6.73-11.79, p < 0.0001) and worse 3-year OS (HR 1.29, 95% CI 1.09-1.51, p = 0.002), while Chinese (HR 0.66, 95% CI 0.60-0.74, p < 0.0001) and Korean patients (HR 0.70, 95% CI 0.59-0.84, p < 0.0001) showed better OS.
conclusionsDisaggregated analysis of AAPI patients revealed significant heterogeneity in EC characteristics and survival. Our findings emphasize collecting subpopulation-level data and tailoring interventions.
Indexed as
Identifiers
40996625What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.